Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -4.43 is 100% above its 5-year average of -256134.32, near the high end of its 5-year range (-697500.00–-4.43).
84.16% above its 12-month average of -27.97.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.33.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-4.43
EARNINGS PER SHARE (EPS) AVG TTM
-27.97
EARNINGS PER SHARE (EPS) AVG 3Y
-98701.49
EARNINGS PER SHARE (EPS) AVG 5Y
-256134.32
EARNINGS PER SHARE (EPS) AVG 10Y
-71227232.36
EARNINGS PER SHARE (EPS) AVG 15Y
-440077566.00
EARNINGS PER SHARE (EPS) AVG 20Y
-910200052.80
CURRENT VS TTM AVG
+84.16%
CURRENT VS 3Y AVG
+100.00%
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
+100.00%
CURRENT VS 15Y AVG
+100.00%
CURRENT VS 20Y AVG
+100.00%
Cerenome, Inc.
Market Cap
$10.94M
Earnings Per Share (EPS)
-4.43
TTM Avg
-27.97
3Y Avg
-98701.49
5Y Avg
-256134.32
Market Cap
$11.00M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.21
3Y Avg
-0.25
5Y Avg
-0.25
Market Cap
$11.02M
Earnings Per Share (EPS)
-1.64
TTM Avg
-2.15
3Y Avg
-4.34
5Y Avg
-5.45
Market Cap
$10.86M
Earnings Per Share (EPS)
-3.20
TTM Avg
-7.58
3Y Avg
-60.73
5Y Avg
-69.78
Market Cap
$10.83M
Earnings Per Share (EPS)
N/A
TTM Avg
-68.10
3Y Avg
-34.05
5Y Avg
-22.70
Market Cap
$11.08M
Earnings Per Share (EPS)
-2.50
TTM Avg
-0.85
3Y Avg
-11.13
5Y Avg
-30.50
Market Cap
$11.12M
Earnings Per Share (EPS)
-1.70
TTM Avg
-1.75
3Y Avg
-3.38
5Y Avg
-5.94
Market Cap
$10.68M
Earnings Per Share (EPS)
-2.45
TTM Avg
-3.00
3Y Avg
-4.04
5Y Avg
-6.77
Market Cap
$11.36M
Earnings Per Share (EPS)
-0.73
TTM Avg
-0.46
3Y Avg
-0.46
5Y Avg
-0.46
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cerenome, Inc. (CNSY) | $10.94M | -4.43 | -27.97 | -98701.49 | -256134.32 |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | -0.21 | -0.25 | -0.25 |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | -1.64 | -2.15 | -4.34 | -5.45 |
| BioVie Inc. (BIVI)vs › | $10.86M | -3.20 | -7.58 | -60.73 | -69.78 |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | -68.10 | -34.05 | -22.70 |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | -2.50 | -0.85 | -11.13 | -30.50 |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | -1.70 | -1.75 | -3.38 | -5.94 |
| Pluri Inc. (PLUR)vs › | $10.68M | -2.45 | -3.00 | -4.04 | -6.77 |
| Caring Brands, Inc. (CABR)vs › | $11.36M | -0.73 | -0.46 | -0.46 | -0.46 |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | -16.53 | -14.84 | -116.30 | -277.16 |
Trailing EPS (TTM)
$-4.43
Forward EPS (Est.)
$-4.75
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -7.19 |
| 2024-12-31 | -48.75 |
| 2023-12-31 | -106000.00 |
| 2022-12-31 | -288750.00 |
| 2021-12-31 | -444500.00 |
| 2020-12-31 | -697500.00 |
| 2019-12-31 | -3101250.00 |
| 2018-12-31 | -32617500.00 |
| 2017-12-31 | -131345500.00 |
| 2016-12-31 | -240000000.00 |
| 2015-12-31 | -374898500.00 |
| 2014-12-31 | -1007767000.00 |
| 2013-12-31 | -984097750.00 |
| 2012-12-31 | -1312154500.00 |
| 2011-12-31 | -1536505750.00 |
| 2010-12-31 | -1417216500.00 |
| 2009-12-31 | -1556032250.00 |
| 2008-12-31 | -2750549500.00 |
| 2007-12-31 | -3200000000.00 |
| 2006-12-31 | -3656178250.00 |
| 2005-12-31 | -4639510500.00 |
| 2004-12-31 | -401923000.00 |
| 2003-12-31 | -1785192250.00 |
| 2002-12-31 | -2407963000.00 |
| 2001-12-31 | -1987056750.00 |
| 2000-12-31 | -188262250.00 |
| 1999-12-31 | -816250000.00 |
| 1998-12-31 | -373214250.00 |
